Opinion|Videos|February 11, 2025
Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC
Author(s)Mark D. Tyson, II, MD, MPH
A panelist discusses how less frequent treatment administration schedules and simpler delivery requirements of newer gene therapies reduce clinic resource burden by minimizing staff time, equipment usage, and biosafety requirements, allowing for more efficient allocation of health care resources.
Advertisement
Episodes in this series
- How does the ability to administer treatments less frequently, once every 3 months, reduce the resource expenditure in your clinic (eg, staff time and equipment use, allocating more time to patients who need more intensive care or follow-up)?
- Newer gene therapies may not require specialized equipment, such as biosafety hoods, for administration. How does this ease the burden on clinics like yours (such as monotherapy, biosafety, no reconstitution or dilution required)?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Permanent J code for mitomycin for intravesical solution now in effect
2
GPS-ProtecT study launched to validate Genomic Prostate Score in active surveillance
3
Real-World Evidence in mCSPC Management
4
FDA updates in urology: December 2025
5